Search Within

Renier J Brentjens

Formats
  1. Meeting Abstract (149)
  2. Journal Article (125)
  3. Review (5)
  4. Editorial (3)
  5. Book Section (1)
  6. Conference Paper (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Adult Leukemia (286)
  2. Center for Hematologic Malignancies (286)
  3. Department of Medicine (286)
  4. GSK Faculty (286)
  5. Hematologic Malignancies Research (286)
  6. Hematologic Malignancies, Division of (286)

More Groups

People
  1. Michel Sadelain (116)
  2. Isabelle Riviere (111)
  3. Jae Park (105)
  4. Xiuyan Wang (66)
  5. Terence Purdon (60)
  6. Elizabeth Halton (48)

More People

Years
  1. 2025 (2)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (17)
  5. 2020 (26)
  6. 2019 (28)

More Years

Publications
  1. Blood (74)
  2. Journal of Clinical Oncology (26)
  3. Molecular Therapy (21)
  4. Cancer Research (10)
  5. Biology of Blood and Marrow Transplantation (8)
  6. Clinical Cancer Research (8)

More Publications

Publishers
  1. American Society of Hematology (79)
  2. Nature Publishing Group (52)
  3. American Association for Cancer Research (29)
  4. American Society of Clinical Oncology (27)
  5. Elsevier Inc. (25)
  6. Cell Press (6)

More Publishers

Results (286)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A systemic xenograft model of Waldenstrom's macroglobulinemia demonstrates the potent anti-tumor effect of second generation CD19 directed chimeric antigen receptor modified T cells in this disease
    Meeting Abstract

    Smith, E. L.; Palomba, M. L.; Park, J. H.; Brentjens, R. J.
    Blood (2014)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Engineered T cell receptor-mimic antibody, (TCRm) chimeric antigen receptor (CAR) T cells against the intracellular protein Wilms tumor-1 (WT1) for treatment of hematologic and solid cancers
    Meeting Abstract

    Rafiq, S.; Dao, T.; Liu, C.; Scheinberg, D. A.; Brentjens, R. J.
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen for the treatment of pediatric relapsed B cell ALL
    Meeting Abstract

    Curran, K. J.; Riviere, I.; Kobos, R.; Kernan, N. A.; Boulad, F.; Prockop, S. E.; Scaradavou, A.; Renaud, T. M.; Shukla, N.; Steinherz, P. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Targeting the cell cycle regulated CDC7 kinase pathway as a novel therapeutic approach for hematologic malignancies
    Meeting Abstract

    Santos, R.; Shum, D.; Churchill, M.; Mukherjee, S.; Brentjens, R. J.; Jurcic, J. G.; Kelly, T.; Djaballah, H.; Frattini, M. G.
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save
  • Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumors
    Meeting Abstract

    Santos, R.; Shum, D.; Carrillo, D.; Zhang, R.; Churchill, M.; Mukherjee, S.; Brentjens, R.; Radu, C.; Kelly, T. J.; Djaballah, H.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • The Warburg effect confers adverse outcome in chronic lymphocytic leukemia
    Meeting Abstract

    Gardner, J. R.; Devlin, S. M.; Knapp, K.; Bauli, F.; Patel, M.; Lamanna, N.; Frattini, M. G.; Brentjens, R.; Maslak, P.; Jurcic, J. G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save
  • Phase I trial of autologous Cd19-targeted car-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated cll
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Haematologica (2014)

    Fulltext@MSK | Save
  • Engineered T Lymphocytes Expressing an Anti-Cd19 Car Specifically Eradicate B-Lymphoma Cells
    Meeting Abstract

    Tsukahara, T.; Ohmine, K.; Uchibori, R.; Urabe, M.; Mizukami, H.; Kume, A.; Riviere, I.; Sadelain, M.; Brentjens, R. J.; Ozawa, K.
    Journal of Gene Medicine (2014)

    Fulltext@MSK | Save